Related Experiment Video
Updated: Jun 21, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[Expression and diagnosis value of Fascin in non-small cell lung cancer patients]
Yu-gang Liu1, Xu-dong Gao, Wen-tao Yue
1Department of Thoracic, Affiliated Hospital of Neimenggu Medical University, Hohhot 010059, China.
Objective:
To evaluate the diagnostic significance of Fascin protein in non-small cell lung cancer (NSCLC) patients.
Methods:
Among 110 cases of NSCLC patients and 50 cases of healthy controls, double antibody sandwich enzyme-linked immunosorbent assay (ELISA) was employed to measure the serum levels of Fascin protein, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), scales like squamous cell carcinoma (SCC) antigen, cytokeratin protein 21-1 (CYFRA21-1) and gastrin-releasing peptide (GRP) precursor. Fascin-positive rate (24.4%) in NSCLC patients was significantly higher than that in healthy controls (4%) (P < 0.05).In different clinical stages of non-small cell lung cancer patients, Fascin-positive rate was statistically significant (P < 0.05). The positive rates of Fascin for CEA, CYFRA21-1, NSE, SCC and Pro-GRP were 25.64%, 5.1%, 5.1%, 5.0% and 1.7% respectively.
Conclusion:
As a new tumor marker, Fascin may be used for clinical screening and prognosis in lung cancer.
